1. Development of a selective agonist for relaxin family peptide receptor 3
- Author
-
Jia-Hui Wang, Ya-Li Liu, Zeng-Guang Xu, Meng-Jun Hu, Zhan-Yun Guo, Wei-Han Nie, Xiao-Xia Shao, and Dian Wei
- Subjects
0301 basic medicine ,Agonist ,Receptors, Peptide ,medicine.drug_class ,Recombinant Fusion Proteins ,Science ,Mutant ,Peptide ,Biology ,Binding, Competitive ,Article ,Receptors, G-Protein-Coupled ,03 medical and health sciences ,Protein Domains ,medicine ,Potency ,Humans ,Insulin ,Amino Acid Sequence ,Receptor ,Peptide sequence ,chemistry.chemical_classification ,Peptide Metabolism ,Relaxin ,Multidisciplinary ,030102 biochemistry & molecular biology ,Proteins ,030104 developmental biology ,HEK293 Cells ,Biochemistry ,chemistry ,Mutation ,Medicine ,Peptides ,Protein Binding - Abstract
Relaxin family peptides perform a variety of biological functions by activating four G protein-coupled receptors, namely RXFP1–4. Among these receptors, RXFP3 lacks a specific natural or synthetic agonist at present. A previously designed chimeric R3/I5 peptide, consisting of the B-chain of relaxin-3 and the A-chain of INSL5, displays equal activity towards the homologous RXFP3 and RXFP4. To increase its selectivity towards RXFP3, in the present study we conducted extensive mutagenesis around the B-chain C-terminal region of R3/I5. Decreasing or increasing the peptide length around the B23–B25 position dramatically lowered the activation potency of R3/I5 towards both RXFP3 and RXFP4. Substitution of B23Gly with Ala or Ser converted R3/I5 from an efficient agonist to a strong antagonist for RXFP3, but the mutants retained considerable activation potency towards RXFP4. Substitution of B24Gly increased the selectivity of R3/I5 towards RXFP3 over the homologous RXFP4. The best mutant, [G(B24)S]R3/I5, displayed 20-fold higher activation potency towards RXFP3 than towards RXFP4, meanwhile retained full activation potency at RXFP3. Thus, [G(B24)S]R3/I5 is the best RXFP3-selective agonist known to date. It is a valuable tool for investigating the physiological functions of RXFP3, and also a suitable template for developing RXFP3-specific agonists in future.
- Published
- 2017